Fennec Pharmaceuticals Inc
FENC
Get informed when a big investor buys or sells
+ FollowMarket Cap$517.59M
Close$
$-9.81
197.3% downside
Current Fair Value
197.3% downsideOvervalued by 197.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $517.59 Million |
|---|---|
| Enterprise Value | $479.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.36 |
| Beta | 1.1 |
| Outstanding Shares | 34,545,000 |
Return
| Return on Equity | -8.69% |
|---|---|
| Return on Assets | -4.87% |
| Return on Invested Capital | -2.70% |
Valuation & Multiples
| P/E Ratio | -77.54 |
|---|---|
| PEG | 47.69 |
| Price to Sales | 10.08 |
| Price to Book Ratio | 10.08 |
| Enterprise Value to Revenue | 8.07 |
| Enterprise Value to EBIT | -280.36 |
| Enterprise Value to Net Income | -131 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$16.21 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$19.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 47.42% |
|---|---|
| Total Invested | $77,900▼ 99.96% |
| Investors Holding | 9▼ 100.00% |
ESG Score
No data
About Fennec Pharmaceuticals Inc
35 employees
CEO: Rostislav Raykov Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation curren...